Cilostazol vs ASA for secondary stroke prevention

By  |  October 27, 2010 | 

This industry funded trial randomized patients with recent stroke (with 6 months) to either cilostazol (100mg bid) or ASA (81mg qday) for a mean of 29 months. The incidence of stroke was significantly lower in the cilostazol group (Hazard ratio 0.74, CI 0.56-0.98), as was the incidence of bleeding (0.77% vs 1.78%). The issue with this drug is cost, BID dosing, and side effects (headache, diarrhea, palpitations, tachycardia, and dizziness). It remains to be seen if the cost and side effect profile outweigh the benefits (reduction of stroke and bleeding) (abstract)

Leave A Comment

About the Author:

Danielle Scheurer
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Categories

Related Posts

By  | July 2, 2015 |  0
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
By  | September 8, 2014 |  3
  As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
By  | July 6, 2013 |  0
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]